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LETTERS TO THE EDITOR

Caesarean < 39 weeks.2 However, the number needed to
treat, as calculated from the study data, is 54 for transient
tachypnea of the newborn and 122 for respiratory distress
syndrome. Further, there is no evidence that corticosteroid
administration improves long term morbidity or mortality.
If there is no clear improvement in long term postnatal
outcomes, it can be argued that another benefit may be
a reduction in resource utilization, as was indeed shown
in the study. However, based on the numbers needed to
treat above and given the large proportion of women who
deliver at between 35 to 38 weeks, such a reduction in
neonatal resource use would be vastly outweighed by the
added visits for maternal counselling regarding antenatal
corticosteroids, in addition to the two visits for injections.
Although the recommendation states that the intervention
“may be considered,” in the absence of specific guidance
about the cases likely to benefit there is no rational basis
for a practitioner to decide whether corticosteroids should
or should not be given in most cases.
To take this analysis further: if corticosteroid administration
is beneficial to the neonate when Caesarean section is
performed at 35 to 38 weeks, why should it not be beneficial
if induction of labour is planned at the same gestational
age? This is a common scenario for cases with maternal
indications such as cholestasis or poorly controlled
diabetes, obstetric indications such as preterm premature
rupture of membranes or prelabour spontaneous rupture
of membranes, and fetal indications such as gastroschisis
or IUGR. This quite reasonable assumption has led some
physicians to start considering antenatal corticosteroids in
such cases too. Why would the same neonatal benefit not
occur in cases with spontaneous labour at 35 to 38 weeks?
In the absence of evidence to the contrary, should we
consider corticosteroid administration for all deliveries at
35 to 38 weeks, planned or spontaneous? Should all women
in latent labour at 35 to 38 weeks receive corticosteroids?
Although the safety concerns for babies exposed antenatally
to corticosteroids should be similar in the post-34 weeks
and 23 to 34 weeks groups, adverse effects including
neurological, cardiovascular, and metabolic outcomes are
possible.3 The risk–benefit ratio may not be as favourable at
35 to 38 weeks as it is at 23 to 34 weeks. In addition, long term
follow up data on postnatal outcomes when corticosteroids
are administered after 34 weeks are limited. The effect of
antenatal corticosteroids on brain development may depend
on gestational age. It has been suggested that early exposure
may only delay myelination, whereas exposure closer to term
could potentially result in cell death.3
The forgoing discussion leads to the conclusion that
there is a need for a recommendation regarding antenatal

corticosteroids, particularly one that addresses pregnancies
at 35 to 38 weeks. I feel that the recommendations
regarding antenatal corticosteroids in this document1
should be removed until a more comprehensive guideline
targeting this topic becomes available. Guidance on use of
antenatal corticosteroids is not essential to this document
as their use is part of standard obstetric care.
Venu Jain, MD, PhD
Department of Obstetrics and Gynaecology,
Royal Alexandra Hospital,
University of Alberta, Edmonton AB
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In Response
To the Editor:
We thank Dr Jain for his letter about the antenatal
corticosteroid recommendation in the 2014 SOGC
guidelines, “Antenatal corticosteroids may be considered for
women delivered by elective Caesarean delivery at ≤ 38+6
weeks’ gestation to reduce respiratory morbidity (1-B; low
quality of evidence/weak recommendation).”1,2 We would
like to emphasize that the strength of the recommendation
was graded as “weak,” consistent with use of “may be
considered” rather than “should be considered.” The
magnitude of bias introduced by lack of blinding in the trial
of Stutchfield et al. is unknown, but the trial nevertheless
provides randomized trial evidence supporting use of
corticosteroids before elective Caesarean.3
We included information on antenatal corticosteroids
for acceleration of fetal pulmonary maturity in our 2014
guideline after debate within the committee. In the end,
we put more weight on having a guideline that was a
comprehensive source of information for maternity care
providers caring for women with a hypertensive disorder of
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pregnancy (HDP), and less weight on mentioning aspects
of care that are not the focus of HDP care. We were happy
to reference other SOGC guidelines for detailed guidance
about aspects of care that are not the focus of HDP care.
However, the SOGC guideline on antenatal corticosteroids
is out of date, having been published in 2002, and so
we referenced more recent guidance related to care in
the Royal College of Obstetricians and Gynaecologists
Green-Top Guideline “Antenatal corticosteroids to reduce
neonatal morbidity.”4
We are uncertain why our recommendation “. . . has
increasingly become a source of confusion for obstetricians
and other practitioners involved in peripartum care of
pregnant women.” The guideline is specifically about
the HDPs, and it would be repetitive to re-state in every
section that recommendations pertain only to women with
one or more of the HDPs. Also, if any woman requires
delivery for maternal or fetal reasons, and waiting 24-48
hours after corticosteroid administration is not deemed
to be of greater benefit than risk, the woman should be
delivered. This is true at 28+4 weeks before an emergency
Caesarean section (for eclampsia, for example) or at 38+4
weeks before an elective Caesarean section in a woman
with chronic hypertension.
Dr Jain questions why antenatal corticosteroids would be
beneficial before elective Caesarean section and not also
for labour induction or even before spontaneous labour.
The literature has already spoken to the benefits of labour
in preparing the neonate for respiratory health postpartum,
and administration of antenatal corticosteroids before
something that is spontaneous (by definition) would
represent not only an impossible challenge but one without
supporting evidence. Importantly, there is no randomized
trial evidence that pertains to delivery plans other than
elective Caesarean section.
Where we agree wholeheartedly with Dr Jain is in the
need for an updated guideline on antenatal corticosteroids,
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to which Dr Jain could contribute his knowledge of the
topic. We will be happy to update our recommendation
and reference that document when it is published.
Laura A. Magee, Anouk Pels, Michael Helewa,
Evelyne Rey, Peter von Dadelszen;
on behalf of the Canadian Hypertensive Disorders of
Pregnancy (HDP) Working Group*
*Francois Audibert, Montreal, QC
Emmanuel Bujold, Quebec, QC
Anne-Marie Côté, Sherbrooke, QC
M Joanne Douglas, Vancouver, BC
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Jennifer Hutcheon, Vancouver, BC
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